Key result
Nilotinib increased the risk of major arterial events compared with imatinib in patients with chronic myeloid leukemia.
Why the study?
Does treatment with tyrosine kinase inhibitors increase the risk of major arterial events in patients with chronic myeloid leukemia?
Meta-Analysis (n=15,706)
Does treatment with tyrosine kinase inhibitors increase the risk of major arterial events in patients with chronic myeloid leukemia?
Answers are grounded in this paper and cite their sources.
In patients with CML, treatment with the TKIs nilotinib and ponatinib is associated with a significantly higher risk of major arterial events compared to imatinib or non-TKI therapies.
There is growing evidence that tyrosine kinase inhibitors (TKIs) may be associated with an increased risk of arterial events. We performed a meta-analysis to estimate the incidence of arterial events in patients with CML treated with TKIs. We identified 29 studies enrolling 15,706 patients. The incidence rates of composite of major arterial events were 0.8 per 100 patient-years for non-TKI treatments, 1.1 per 100 patient-years for dasatinib, 0.1 per 100 patient-years for imatinib, 0.4 per 100 patient-years for bosutinib, 2.8 per 100 patient-years for nilotinib and 10.6 per 100 patient-years for ponatinib. The relative risk (RR) for nilotinib compared with imatinib suggests a significantly increased risk of the composite of major arterial events with nilotinib treatment (RR 5.3; 95%CI 3.0-9.3, p < 0.001). This study demonstrates that, patients who received nilotinib or ponatinib had a greater number of major arterial events when compared to non-TKI-, imatinib-, dasatinib- and bosutinib-treated patients.
No takes yet. Share an insight, caveat, or question.
Chai‐Adisaksopha et al. (2015) conducted a meta-analysis in chronic myeloid leukemia (n=15,706). Nilotinib vs. Imatinib was evaluated on composite of major arterial events (RR 5.3, 95% CI 3.0-9.3, p=< 0.001). Nilotinib increased the risk of major arterial events compared with imatinib in patients with chronic myeloid leukemia.
Synapse has enriched 10 related papers. Consider them for comparative context: